Request Trial
shutterstock_1595586766_ken_wolter
Ken Wolter / Shutterstock.com
6 March 2020PharmaClaire Irvine

Broad Institute down (but not out) in the European fight over CRISPR IP

Following the upholding in January 2020 of the revocation of the Broad Institute’s lead European patent (EP 2771468) by a European Patent Office (EPO) Appeal Board, there has been speculation that the University of California and its co-applicants (UC) have the upper hand in the European fight over the IP of clustered regularly interspaced short palindromic repeats (more commonly known as ‘CRISPR’), the latest incarnation of genome editing and deliberate alteration.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
USPTO director steps into Sun Pharma’s PTAB-ITC clash
31 July 2026   A director review has overturned a PTAB ruling, questioning why it diverged from an ITC decision based on the same patent claims, prior art and evidence.
Pharma
Pharmascience v Janssen: Canada court updates methods of medical treatment protection
23 July 2026   Canada has firmly slammed the door on patenting methods of medical treatment—but the battle over what counts as a "medical method" is only just beginning. Scott MacKendrick of ROBIC examines a landmark decision that leaves the door ajar for future litigation over complex drug-dosing regimens.
Pharma
Exelixis opens two-front patent dispute over Cabometyx copies
9 July 2026   Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.


Editor's picks

Where Big Pharma is betting big in the M&A boom
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026

Editor's picks

Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026

More features

USPTO director steps into Sun Pharma’s PTAB-ITC clash
Where Big Pharma is betting big in the M&A boom
Buying the brains: Why is Big Pharma shopping for innovation?
Trump slaps 100% tariff on generic drugs in US manufacturing push
Pharmascience v Janssen: Canada court updates methods of medical treatment protection
Why is 2026 already a record year for M&A activity?
Illumina ordered to recall products after German patent ruling
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer